Matinas Biopharma (MTNB) Competitors $0.58 +0.01 (+1.20%) Closing price 04:00 PM EasternExtended Trading$0.57 -0.01 (-1.88%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends MTNB vs. TXMD, CLRB, CLDI, ACXP, PMCB, APLM, PHIO, BCLI, TSBX, and JAGXShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include TherapeuticsMD (TXMD), Cellectar Biosciences (CLRB), Calidi Biotherapeutics (CLDI), Acurx Pharmaceuticals (ACXP), PharmaCyte Biotech (PMCB), Apollomics (APLM), Phio Pharmaceuticals (PHIO), Brainstorm Cell Therapeutics (BCLI), Turnstone Biologics (TSBX), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. TherapeuticsMD Cellectar Biosciences Calidi Biotherapeutics Acurx Pharmaceuticals PharmaCyte Biotech Apollomics Phio Pharmaceuticals Brainstorm Cell Therapeutics Turnstone Biologics Jaguar Health Matinas Biopharma (NYSE:MTNB) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Does the MarketBeat Community favor MTNB or TXMD? TherapeuticsMD received 386 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/ATherapeuticsMDOutperform Votes38658.57% Underperform Votes27341.43% Which has higher earnings & valuation, MTNB or TXMD? TherapeuticsMD has higher revenue and earnings than Matinas Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M2.68-$22.94M-$4.85-0.12TherapeuticsMD$1.60M7.59-$10.28MN/AN/A Is MTNB or TXMD more profitable? Matinas Biopharma has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% TherapeuticsMD -207.77%-14.08%-9.61% Which has more volatility & risk, MTNB or TXMD? Matinas Biopharma has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Do analysts rate MTNB or TXMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of MTNB or TXMD? 11.8% of Matinas Biopharma shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 9.6% of Matinas Biopharma shares are owned by insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor MTNB or TXMD? In the previous week, TherapeuticsMD had 1 more articles in the media than Matinas Biopharma. MarketBeat recorded 1 mentions for TherapeuticsMD and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score. Company Overall Sentiment Matinas Biopharma Neutral TherapeuticsMD Neutral SummaryTherapeuticsMD beats Matinas Biopharma on 8 of the 12 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.95M$6.58B$5.40B$20.05BDividend YieldN/A2.96%5.37%3.61%P/E Ratio-0.1210.0188.8341.75Price / Sales2.68335.371,284.8717.51Price / CashN/A22.6336.6017.54Price / Book0.135.084.965.86Net Income-$22.94M$154.90M$117.89M$1.01B7 Day Performance-17.16%2.59%2.74%3.59%1 Month Performance6.40%1.52%3.63%6.09%1 Year PerformanceN/A5.49%27.26%20.27% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.58+1.2%N/AN/A$2.95M$1.10M-0.1230Gap DownTXMDTherapeuticsMD0.616 of 5 stars$1.04-5.4%N/A-52.5%$11.99M$1.60M0.00420CLRBCellectar Biosciences2.8478 of 5 stars$0.29+2.7%$17.67+5,992.0%-93.0%$11.97MN/A-0.1710Analyst ForecastHigh Trading VolumeCLDICalidi Biotherapeutics3.0694 of 5 stars$0.91-0.2%$16.67+1,724.9%N/A$11.94M$50,000.000.0038ACXPAcurx Pharmaceuticals3.033 of 5 stars$0.70-12.9%$12.00+1,604.5%-76.1%$11.89MN/A-0.653Short Interest ↓PMCBPharmaCyte BiotechN/A$1.53+0.7%N/A-28.7%$11.75MN/A2.892APLMApollomics2.3923 of 5 stars$10.74+1.9%$200.00+1,763.1%-89.3%$11.67M$1.22M0.0045PHIOPhio Pharmaceuticals2.5091 of 5 stars$7.72+356.8%$36.00+366.3%-54.4%$11.52MN/A-0.7110High Trading VolumeBCLIBrainstorm Cell Therapeutics4.5373 of 5 stars$2.02-0.2%$30.00+1,388.8%-55.1%$11.49MN/A-0.4240Analyst UpgradeNews CoverageGap UpTSBXTurnstone Biologics3.0592 of 5 stars$0.48-0.9%$2.13+346.4%-77.0%$11.01M$19.31M-0.1582News CoverageJAGXJaguar Health0.5596 of 5 stars$0.93-7.0%N/A-86.1%$10.97M$10.48M0.0050 Related Companies and Tools Related Companies TXMD Alternatives CLRB Alternatives CLDI Alternatives ACXP Alternatives PMCB Alternatives APLM Alternatives PHIO Alternatives BCLI Alternatives TSBX Alternatives JAGX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:MTNB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
